Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cadrenal Therapeutics, Inc. ( (CVKD) ).
On March 12, 2026, Cadrenal Therapeutics highlighted new preclinical research on CAD-1005, a first-in-class 12-LOX inhibitor, showing its potential to address inflammatory complications of obesity and Type 2 diabetes. In animal models, oral CAD-1005 improved glycemic control, reduced pancreatic β-cell loss, decreased inflammatory cell infiltration in adipose and pancreatic tissues, and lowered pro-inflammatory cytokine levels.
The findings position 12-LOX as a key driver of obesity-related inflammation and suggest that CAD-1005’s mechanism, already in clinical development for heparin-induced thrombocytopenia, could extend into metabolic disease indications. This dual application may enhance Cadrenal’s strategic profile in both rare immune-mediated thrombosis and broader chronic inflammatory conditions, while its near-term operational focus remains on advancing CAD-1005 for HIT following positive Phase 2 data on thrombotic event reduction.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Neutral.
The score is primarily held down by weak financial performance (no revenue, widening losses, and significant cash burn with likely external funding needs). Technicals are mixed but still skew negative versus longer-term moving averages, and valuation metrics are limited by losses. Offsetting these risks, recent corporate events modestly improve the outlook by strengthening the pipeline and leadership.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. Its lead candidate, CAD-1005, is a first-in-class 12-lipoxygenase inhibitor for treating heparin-induced thrombocytopenia, and its pipeline includes second-generation 12-LOX oral therapeutics, tecarfarin, and frunexian.
The company targets niche and high-risk cardiovascular and hematologic indications, aiming to improve outcomes where current anticoagulation and anti-thrombotic options are limited. CAD-1005 has received Orphan Drug and Fast Track designations in the U.S., as well as orphan status in Europe, underscoring its potential role in specialized hospital and chronic-care settings.
Average Trading Volume: 60,140
Technical Sentiment Signal: Sell
Current Market Cap: $18.24M
Learn more about CVKD stock on TipRanks’ Stock Analysis page.